Expert consensus on the detection and clinical management of familial hypercholesterolemia

被引：10

作者：

Masana, Lluis ^{[1
]}

Civeira, Fernando ^{[1
]}

Pedro-Botet, Juan ^{[1
]}

de Castro, Isabel ^{[1
]}

Pocovi, Miguel ^{[1
]}

Plana, Nuria ^{[1
]}

Mateo-Gallego, Rocio ^{[1
]}

Jarauta, Estibaliz ^{[1
]}

Pedragosa, Angels ^{[1
]}

机构：

[1] Soc Espanola Arteriosclerosis, Barcelona, Spain

来源：

CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS | 2013年 / 25卷 / 04期

关键词：

Familial hypercholesterolemia; Guidelines; Clinical management;

D O I：

10.1016/j.arteri.2013.07.005

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Familial hypercholesterolemia (FH) is one of the most common and severe genetic diseases, causing disabilities and premature death to those who suffer it. Lipid-lowering therapy substantially improves the prognosis of FH patients and, therefore, appropriate pharmacological treatment is of the utmost importance. The Spanish Society of Arteriosclerosis (SEA) has always been a pioneer in the diagnosis and treatment of FH. Since its inception, FH has been one of the main areas of clinical and scientific interest, mainly for Lipids Units of the SEA, where most patients with this pathology are referred in Spain. This document arises from the willingness of our society to update the scientific knowledge on this subject and to provide physicians with clear clinical guidelines regarding diagnosis and treatment of FH. These guidelines can be summarized in two main aspects: early diagnosis of the disease and a rapid normalization of LDL cholesterol. In the coming years, health providers should accomplish that the majority of patients with FH are aware of their diagnosis and that adequate treatment is provided. (C) 2013 Elsevier Espana, S.L. y SEA. All rights reserved.

引用

页码：182 / 193

页数：12

共 47 条

[1] Goldstein J.L., Hobbs H.H., Brown M.S., Familial hypercholesterolemia, The Metabolic and Molecular Bases of Inherited Disease, pp. 2863-2913, (2001)
[2] Goldstein J.L., Brown M.S., Familial hypercholesterolemia: Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol, Proc Natl Acad Sci U S A, 70, pp. 2084-2088, (1973)
[3] Marduel M., Ouguerram K., Serre V., Bonnefont Rousselot D., Marques-Pinheiro A., Erik Berge K., Et al., Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation, Hum Mutat, 34, pp. 83-87, (2013)
[4] Civeira F., Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis, 173, pp. 55-68, (2004)
[5] Palacios L., Grandoso L., Cuevas N., Olano-Martin E., Martinez A., Tejedor D., Et al., Molecular characterization of familial hypercholesterolemia in Spain, Atherosclerosis, 221, pp. 137-142, (2012)
[6] Rader D.J., Cohen J., Hobbs H.H., Monogenic hypercholesterolemia: New insights in pathogenesis and treatment, J Clin Invest, 111, pp. 1795-1803, (2003)
[7] Junyent M., Gilabert R., Jarauta E., Nunez I., Cofan M., Civeira F., Et al., Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia, Atherosclerosis, 208, pp. 437-441, (2010)
[8] Innerarity T.L., Weisgraber K.H., Arnold K.S., Mahley R.W., Krauss R.M., Vega G.L., Et al., Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding, Proc Natl Acad Sci U S A, 84, pp. 6919-6923, (1987)
[9] Marais D.A., Blom D.J., Petrides F., Goueffic Y., Lambert G., Proprotein convertase subtilisin/kexin type 9 inhibition, Curr Opin Lipidol, 23, pp. 511-517, (2012)
[10] Talmud P.J., Shah S., Whittall R., Futema M., Howard P., Cooper J.A., Et al., Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study, Lancet, 381, pp. 1293-1301, (2013)

← 1 2 3 4 5 →